Does Dr. CHAD BRIZENDINE have financial conflicts of interest?

Dr. CHAD BRIZENDINE (MD) has received a total of $268 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $268 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. CHAD BRIZENDINE?

According to CMS Open Payments data, Dr. CHAD BRIZENDINE received funding from PULMONX CORPORATION ($145), ASTRAZENECA PHARMACEUTICALS ($84), and BOEHRINGER INGELHEIM PHARMACEUTICALS ($40).

Does Dr. CHAD BRIZENDINE receive research grants or speaking fees?

Dr. CHAD BRIZENDINE has received $268 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. CHAD BRIZENDINE

MDReal-Time Hydrated

Specialty: Internal Medicine, Pulmonary Disease

Practice Location: COEUR D ALENE, ID 83814

NPI Number: 1376991802

LIFETIME INDUSTRY VALUE

$268

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. BRIZENDINE is a verified Internal Medicine, Pulmonary Disease practitioner based in COEUR D ALENE, ID.

Between 2021 and 2025, Dr. BRIZENDINE had an overall industry promotional and research financial footprint of $268 as recorded in the federal CMS Open Payments database.

$268 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. BRIZENDINE's primary funding source is PULMONX CORPORATION, which accounts for $145 (representing 53.9% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

PULMONX CORPORATION

Rank 1

$145

53.9%

ASTRAZENECA PHARMACEUTICALS

Rank 2

$84

31.1%

BOEHRINGER INGELHEIM PHARMACEUTICALS

Rank 3

$40

15%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.